British Biotech nears cancer drug deal
Tuesday 07 September 1999
A company source yesterday said a deal was "imminent". Shares in the company closed up 6.25p, or 20 per cent, at 37.25p yesterday following reports at the weekend that a licensing deal would be announced the company's annual meeting, scheduled for 23 September.
However, it now appears a deal is ready to be signed. Possible candidates for the partnership include US groups Merck, Pharmacia & Upjohn, and Eli Lilly.
The partnership agreement is expected to take the form of an upfront licence fee, with regular milestone payments tied to further trials.
The deal follows the publication last month of mixed results for Marimastat, a treatment for gastric cancer, in clinical trails. While the drug failed in its primary goal of prolonging overall survival significantly at a pre-determined end-point, the company claims it was successful if the data from nine patients, who violated the trial's protocol, were discounted.
The drug showed also significant effects in arresting the development of tumours, a secondary target of the study, prompting the company to approach regulators for possible marketing approval of the drug.
Even if Marimastat becomes a commercial product, it may not lead to a revival in the fortunes of British Biotech, whose shares crashed in 1997 after one its directors took issue publicly with its statements about drugs in development. The company's management has since been overhauled.
While there is no available treatment for gastric cancer after chemotherapy or operation, some observers doubt whether doctors would allocate resources to a treatment which adds perhaps only days to a patient's life.
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
Rap music mogul accused of running two men over in his truck
World cities ranked in terms of safety, food security and 'liveability'
First full-length look is finally here
"Oink! Oink! Hee hee hee!" First interview with the big-screen star
Biohacking group hopes technology will lead people to think about even more dystopian uses
The party's potential nominations read like a high school race for student body president
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Mia Khalifa: Pornhub star claims Drake sent her 'cringeworthy' naked photos on Instagram
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
Ball pool for adults opens in London
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...